Impact of chemotherapy on early ageing in testicular cancer patients
Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study
This study tests how chemotherapy for testicular cancer affects aging in patients by looking at changes in their skin and fat cells.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 192 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Male |
| Sponsor | University Medical Center Groningen Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Groningen) |
| Trial ID | NCT04113122 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of cisplatin-combination chemotherapy on the development of senescent cells and an early ageing phenotype in patients with metastatic testicular cancer. It aims to understand how chemotherapy-induced DNA damage affects both tumor and healthy cells, potentially leading to long-term health consequences. The study includes both cross-sectional and longitudinal components, involving skin and subcutaneous fat biopsies to assess cellular changes. By examining these effects, the researchers hope to uncover mechanisms behind late effects of treatment.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with metastatic testicular cancer who are younger than 50 years and have received or are about to receive cisplatin-based chemotherapy.
Not a fit: Patients who are older than 50 years or have not received cisplatin-based chemotherapy for metastatic testicular cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of long-term health issues faced by testicular cancer survivors.
How similar studies have performed: While the specific approach of this study may be novel, there is growing interest in understanding the long-term effects of chemotherapy on cellular ageing, with some related studies showing promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: In order to be eligible to participate in the cross-sectional part of this study, a subject must meet all of the following criteria: * Diagnosed with metastatic testicular cancer in 1999-2012 (stage II or higher) * Received first-line cisplatin-based chemotherapy * Was younger than 50 years of age at start of chemotherapy In order to be eligible to participate in the longitudinal part of this study, a subject must meet all of the following criteria: Chemotherapy-group: * Diagnosis of metastatic testicular cancer (stage II or higher) * Is about to start with first-line cisplatin-based chemotherapy * Younger than 50 years of age at diagnosis of metastatic testicular cancer Stage I control-group: * Diagnosis of testicular cancer stage I disease * Younger than 50 years of age at diagnosis of testicular cancer Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: \- Not able to provide informed consent (in example in case of mental or psychiatric disability)
Where this trial is running
Groningen
- University Medical Center Groningen — Groningen, Netherlands (Recruiting)
Study contacts
- Principal investigator: J. A. Gietema, Prof. — University Medical Center Groningen
- Study coordinator: J. A. Gietema, prof.
- Email: j.a.gietema@umcg.nl
- Phone: +31 50 361 2821
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.